If you are attending the Alliance for Regenerative Medicine's 2024 Cell & Gene Meeting on the Mesa, be sure to check out our company presentation on Wednesday, October 9th, at 9:15 a.m. MST, given by Chief Scientific Officer, Dr. Timothy Kieffer. Looking forward to connecting with other thought leaders to tackle the most pressing issues facing cell and gene therapy. #CGMesa24 #cellandgenetherapy #Fractyl #FractylFirst #obesity #T2D
Fractyl Health
Biotechnology Research
Lexington, MA 7,480 followers
Dedicated to novel therapeutic interventions that can reverse the metabolic disease epidemic.
About us
Fractyl Health is developing innovative therapies to address the root cause of type 2 diabetes and obesity. Our groundbreaking research and biological insights showed the key role of the intestine in metabolic control. Our lead program, Revita, is designed to target and control the intestine for the treatment of metabolic disease. Revita is a first-in-class procedural therapy that is now in late-stage clinical trials for the treatment of type 2 diabetes. Our pipeline also includes Rejuva, a pancreatic gene therapy, which is in preclinical development for restoration of beta cell health in type 2 diabetes. Our team is made up of passionate innovators at the intersection of biology and technology, working to deliver better real-world outcomes for people with metabolic disease. Fractyl Health is located in Burlington, Mass.
- Website
-
http://www.fractyl.com
External link for Fractyl Health
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Lexington, MA
- Type
- Privately Held
- Founded
- 2010
Locations
-
Primary
Get directions
17 Hartwell Avenue
Lexington, MA 02421, US
Employees at Fractyl Health
Updates
-
We were thrilled that our Co-founder and CEO, Harith Rajagopalan, took part in a panel discussion this week at the 2024 World Medical Innovation Forum #WMIF2024. During the discussion entitled “The Disruptors: Metabolic Power…Need it…Want it,” Dr. Rajagopalan discussed how Fractyl is breaking the pattern of chronic disease management in obesity and type 2 diabetes with our innovative solutions. To learn more, visit our website: www.fractyl.com. #WMIF2024 #obesity #type2diabetes #T2D #FractylHealth #FractylForward
-
-
At Fractyl Health, our mission is to innovate new solutions for people living with #obesity and #T2D. For Emily Sorrentine, Associate Director, Procedural Training, Medical Affairs, the people she works with each day are a testament to Fractyl Health’s approach and values. #FractylForward
-
-
Last week, our CEO, Harith Rajagopalan, shared our latest innovations in #obesity and #T2D care with fellow industry leaders at the Morgan Stanley 12th Annual Laguna Conference and the H.C. Wainwright & Co., LLC 26th Annual Global Investor Conference. We appreciated connecting with our peers and look forward to next year’s meetings! #MorganStanley #HCWainwrightGlobal
-
-
Fractyl is excited to be a part of this week’s European Association for the Study of Diabetes e.V. (EASD) meeting in Madrid, Spain. On Wednesday, September 11th, Chief Scientific Officer Tim Kieffer, Ph.D., presented encore preclinical data for our investigational product REJUVA®. You can find the presentation here: https://lnkd.in/ePiqfB_g. We look forward to next year's meeting! *Rejuva is in preclinical development and has yet to be assessed by regulatory agencies #EASD2024 #Fractyl #obesity #type2diabetes #T2D #biotech
-
-
#News for #Investors: Our Co-founder and CEO, Harith Rajagopalan, M.D., Ph.D., will present at two upcoming investor conferences: Morgan Stanley Global Healthcare Conference Format: Fireside Chat Date: 09/06/2024 Time: 10:45 AM ET H.C. Wainwright 26th Annual Global Investment Conference Format: Company Presentation Date: 09/09/2024 Time: 2:00 PM ET Webcast replays will be accessible following the live sessions on the Events page of the Investors section on our website at https://ir.fractyl.com/.
-
We're continuing to take steps to make a meaningful difference for #patients. Read more about Fractyl Health’s (#NASDAQ: GUTS) Q2 financial results and our potentially novel approach to weight maintenance here: https://bit.ly/3YJupri #FractylHealthNews
-
-
Exciting one-year follow-up data from #Germany shows positive results in lowering and maintaining both #WeightLoss and #BloodSugar. Learn more about the potential impact on people living with #obesity and #T2D: https://bit.ly/3AfB1DT #FractylHealthNews
-
-
#FractylHealthNews: We’re thrilled to share the FDA has granted Breakthrough Device Designation for Fractyl Health’s Revita in weight maintenance after discontinuation of #GLP1 drugs. This designation is given to expedite review of promising technologies that can improve the lives of people with life-threatening or debilitating conditions. Learn more: https://bit.ly/4c7ViZd
-
-
We had a wonderful time meeting with key stakeholders from around the world at this year’s American Diabetes Association (ADA) 84th Scientific Sessions. To read about the data we presented for our preclinical product candidate REJUVA® which was selected as the number one abstract out of 8,000 submissions by the Scientific Sessions Meeting Planning Committee, click here: https://lnkd.in/eTVrZWEf To hear a recap of our KOL event with Dr. David D’Alessio, visit the IR page on Fractyl.com. We look forward to seeing you again next year. *Rejuva is in preclinical development and has yet to be assessed by regulatory agencies #ADA2024 #ADAScientificSessions #Fractyl #obesity #type2diabetes #T2D #biotech
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions | Fractyl Health, Inc.
ir.fractyl.com